Silence Therapeutics plc (SLN) P/S ratio

P/S ratio today
1673.0×

Silence Therapeutics plc (SLN) trades at 1673.0× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 7.4×. That is 63.9% lower than the 20.4× of fiscal 2023. Figures as of 18 Nov 2026, 13:09 UTC, from Yahoo Finance.

Key facts

P/S ratio today
1673.0×
P/S ratio, fiscal 2024
7.4×
Change on fiscal 2023
−63.9%
Highest on record
22.7×fiscal 2022
Lowest on record
7.4×fiscal 2024
Fiscal years on record
32022–2024

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Silence Therapeutics plc P/S ratio, in more detail

Today's figure is 22642.9% above the fiscal 2024 year-end.

Across the 3 fiscal year-ends on record (2022–2024), the highest was 22.7× in fiscal 2022 and the lowest 7.4× in fiscal 2024. Today's P/S ratio is above every one of the 3 fiscal year-ends on record; their median is 20.4×.

History · 3 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Silence Therapeutics plc P/S ratio, year by year

Silence Therapeutics plc (SLN) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today1673.0×—$19.80—
2025——$6.08$0.01
20247.4× 63.9% down$6.88$0.94
202320.4× 10.2% down$17.37$0.85
202222.7×—$15.25$0.67

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on SLN

Silence Therapeutics plc, figure by figure

Silence Therapeutics plc (SLN) overview: price, valuation and scorecard

Silence Therapeutics plc P/S ratio: questions and answers

What is Silence Therapeutics plc's P/S ratio?

Silence Therapeutics plc (SLN) trades at 1673.0× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 7.4×. That is 63.9% lower than the 20.4× of fiscal 2023.

Is Silence Therapeutics plc's P/S ratio high or low compared with its own history?

Today's P/S ratio is above every one of the 3 fiscal year-ends on record; their median is 20.4×.

What are the highest and lowest P/S ratio figures on record for Silence Therapeutics plc?

Across the 3 fiscal year-ends on record (2022–2024), the highest was 22.7× in fiscal 2022 and the lowest 7.4× in fiscal 2024.

How is Silence Therapeutics plc's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Silence Therapeutics plc it is on record here for 3 fiscal years, 2022 to 2024.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Silence Therapeutics plc (SLN) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/SLN/ps-ratio

Underlying data: Yahoo Finance.